

**18 May 2021**

Australian Securities Exchange  
20 Bridge Street,  
Sydney NSW 2000

## **Change of Directors' Holdings**

### **Highlights:**

- Ms Rebecca Wilson (Alcidion Chair) has acquired 15,327 shares in the recently completed SPP
- Ms Robyn Morris (spouse of NED Raymond Blight) has acquired 93,750 shares in the SPP
- MKMS Investment Trust has sold 11.48 million shares during the current trading window
- MKMS Investment Trust, owned by the former owners of MKM Health which was acquired by Alcidion in 2018, is being dissolved following the share sale
- Mr Simon Chamberlain (NED) has acquired 295,000 shares as part of the MKMS disposal

**Melbourne, Australia** – Alcidion Group Limited (ASX: ALC) board has today been advised of a change in shareholding by several directors, two of whom are substantial shareholders.

MKMS Investment Pty Ltd <MKMS Investment Trust> (MKMS) has sold all the 11.48 million ALC shares that it held through a broker managed on-market transaction. The sale of shares was undertaken at \$0.34 per share.

MKMS is an entity owned by the five former owners of MKM Health to manage MKM Health's investment in Patientrack, both of which were acquired by Alcidion in 2018. MKMS is no longer an appropriate investment vehicle for the individual parties involved and is therefore being dissolved, requiring the sale of its interest in Alcidion. The unit holders of MKMS include current and retired employees of Alcidion, who each continue to hold significant individual shareholdings in Alcidion. Kate Quirke's interest in MKMS equated to 1,497,557 million shares, representing approximately 3% of her shareholding. Ms Quirke retains a cumulative total of 46,561,285 shares.

Simon Chamberlain, a non-executive director, has acquired 295,000 shares at \$0.34 as part of the MKMS managed sale.

Ms Rebecca Wilson and Ms Robyn Morris (spouse of NED Raymond Blight) subscribed for further shares in the SPP, receiving 15,327 and 93,750 shares, respectively after having their original applications scaled back in a manner consistent with other SPP applicants. Ms Wilson now holds 1,517,924 shares in Alcidion.

In accordance with the ASX listing rules, relevant change in Director and Substantial Shareholder disclosures will be released as appropriate.

Rebecca Wilson, Alcidion Chair said, "The sale of MKMS shares to Simon Chamberlain along with several institutional shareholders further reflects the strong underlying support for Alcidion and assists in maintaining an orderly market as the MKMS structure is dissolved. All of the underlying unit holders in MKMS remain significant shareholders in Alcidion, with everyone excited by the growth opportunities that lie ahead".

**ENDS**

For further information, please contact:

**Kyahn Williamson**

WE Communications

Ph: +61 401 018 828

[kwilliamson@we-worldwide.com](mailto:kwilliamson@we-worldwide.com)

### **About Alcidion Group Limited (ASX: ALC)**

Alcidion Group Limited (Alcidion) has a simple purpose: to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 300 hospitals and 60 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

[www.alcidion.com](http://www.alcidion.com)

© Alcidion Group Limited 2021. Alcidion, Miya Precision, Patientrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

This announcement is authorised for release by the Board of Directors of Alcidion Group Limited.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>ALCIDION GROUP LIMITED</b>
<b>ABN</b>	<b>77 143 142 410</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Katrina Elizabeth Doyle (aka Kate Quirke)
<b>Date of last notice</b>	23 November 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<p>MNMD Pty Ltd &lt;Quirke Superannuation Fund&gt; (Sole Director and Beneficiary) <b>(MNMD)</b></p> <p>MKMS Investment Pty Ltd &lt;MKMS Investment Trust&gt; (Director and Unit Holder) <b>(MKMS)*</b></p> <p>Robin Michael Doyle &lt;The Doyle Super Fund&gt; (Joint Trustee) <b>(RMD)</b></p>
<b>Date of change</b>	17 May 2021
<b>No. of securities held prior to change</b>	<p><b>Direct</b></p> <p>27,793,199 Fully Paid Ordinary Shares</p> <p>2,547,511 Performance Rights expiring 31.10.2023</p> <p><b>Indirect</b></p> <p>18,668,086 Fully Paid Ordinary Shares <b>(MNMD)</b></p> <p>100,000 Fully Paid Ordinary Shares <b>(RMD)</b></p> <p>11,481,273 Fully Paid Ordinary Shares <b>(MKMS)</b></p>
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	-
<b>Number disposed</b>	<p>11,481,273*</p> <p><i>Katrina Doyle's beneficial interest in ALC shares held by MKMS is 1,497,557 shares.</i></p>

*\*Katrina Elizabeth Doyle's beneficial interest in ALC shares held by MKMS equates to 13% of MKMS's total holding*

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$3,903,632.82 (\$0.34 per share) <i>The value of Katrina Doyle's beneficial interest ALC shares disposed of by MKMS was \$509,169.38.</i>
<b>No. of securities held after change</b>	<b>Direct</b> 27,793,199 Fully Paid Ordinary Shares 2,547,511 Performance Rights expiring 31.10.2023  <b>Indirect</b> 18,668,086 Fully Paid Ordinary Shares ( <b>MNMD</b> ) 100,000 Fully Paid Ordinary Shares ( <b>RMD</b> )
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>ALCIDION GROUP LIMITED</b>
<b>ABN</b>	<b>77 143 142 410</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Raymond Howard Blight
<b>Date of last notice</b>	28 August 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Ms Robyn Gaile Morris (Spouse of Mr Raymond Blight)
<b>Date of change</b>	11 May 2021
<b>No. of securities held prior to change</b>	<b>Direct</b> 96,028,781 Fully Paid Ordinary Shares  <b>Indirect</b> 4,549,300 Fully Paid Ordinary Shares
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	<b>Indirect</b> 93,750 Fully Paid Ordinary Shares
<b>Number disposed</b>	-
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.32 per share

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<b>Direct</b> 96,028,781 Fully Paid Ordinary Shares  <b>Indirect</b> 4,643,050 Fully Paid Ordinary Shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued pursuant to Share Purchase Plan announced on 15 April 2021

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>ALCIDION GROUP LIMITED</b>
<b>ABN</b>	<b>77 143 142 410</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Rebecca Wilson
<b>Date of last notice</b>	12 March 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Parker and Wilson Investment Pty Ltd <Parker & Wilson Superannuation Fund> (Director and Beneficiary)
<b>Date of change</b>	11 May 2021
<b>No. of securities held prior to change</b>	<b>Direct</b> 570,000 Fully Paid Ordinary Shares  <b>Indirect</b> 910,000 Fully Paid Ordinary Shares
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	<b>Direct</b> 15,327 Fully Paid Ordinary Shares  <b>Indirect</b> 22,597 Fully Paid Ordinary Shares
<b>Number disposed</b>	-
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$12,135.68

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>No. of securities held after change</b>	<b>Direct</b> 585,327 Fully Paid Ordinary Shares  <b>Indirect</b> 932,597 Fully Paid Ordinary Shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued pursuant to Share Purchase Plan announced on 15 April 2021

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.



# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>ALCIDION GROUP LIMITED</b>
<b>ABN</b>	<b>77 143 142 410</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Simon Chamberlain
<b>Date of last notice</b>	1 July 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Bright Ventures Super Pty Ltd <Bright Ventures S/F A/C>
<b>Date of change</b>	17 May 2021
<b>No. of securities held prior to change</b>	-
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	<b>Indirect</b> 295,000 Fully Paid Ordinary Shares
<b>Number disposed</b>	-
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$100,300
<b>No. of securities held after change</b>	<b>Indirect</b> 295,000 Fully Paid Ordinary Shares
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On-market trade

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.